医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

RIVA a Key Component of Licensed Manufacturing Process for Chemotherapy Drugs in Australia

2015年01月05日 PM11:37
このエントリーをはてなブックマークに追加


 

WINNIPEG, Manitoba

Intelligent Hospital Systems (IH Systems) today announced the Australian Therapeutic Goods Administration (TGA), that nation’s equivalent of the U.S. Food and Drug Administration, has approved a workflow process in which one of Australia’s largest pharmaceutical compounders will use RIVA technology to produce patient chemotherapy doses. This is the first time the TGA has approved a drug compounding process that includes a fully automated IV compounding system in a Current Good Manufacturing Practice (cGMP) facility.

“We are excited to demonstrate the benefits of integrating IV automation technology in compounding chemotherapy medications,” said Dr. Niels Erik Hansen, president and CEO of IH Systems. “This is an important recognition that the processes, safety features and airflow design of RIVA meet the strict requirements for sterile compounding in a cGMP environment.”

The TGA is part of the Australian government’s Department of Health and responsible for regulating therapeutic goods including prescription medicines and devices, among other things. IH Systems and the compounder worked together extensively on the necessary validation of the RIVA Chemotherapy system to demonstrate the technology and processes meet TGA’s stringent requirements. With TGA’s approval, the system is now in production manufacturing doses for Australia and New Zealand.

“This is a very important step forward in pharmaceutical compounding and represents the leading edge of integrating fully automated compounding into cGMP production processes,” said Dr. Hansen. “RIVA provides a technology platform that allows drug makers to maintain rigorous compounding standards while meeting customer and patient needs.”

The partnership is significant and may provide a model for future drug production in other highly regulated countries or compounding environments, Dr. Hansen added.

About Intelligent Hospital Systems

Founded in 2006, Intelligent Hospital Systems (IH Systems) is a medical device company focused on the design and development of automated solutions for the hospital environment. Based in Winnipeg, Manitoba, IH Systems manufactures RIVA, a fully automated IV compounding system that prepares medications for syringes and IV bags in an aseptic environment. Using RIVA, hospitals enhance patient safety, lower the cost-per-dose of medications, reduce their vulnerability to medication shortages and cut waste. For more information, visit http://www.intelligenthospitals.com/.

CONTACT

For IH Systems
Cookerly Public Relations
Cory Stewart,
404-816-2037
cory@cookerly.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024